Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Completed 38Unknown 6Terminated 3Recruiting 3Withdrawn 2Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 1

Conditions

Vomiting 1Neoplasms, Germ Cell and Embryonal 1Nausea 1Lymphoma, Non-Hodgkin 1Lymphoma 1

Interventions

Cyclophosphamide 128Cisplatin 119Radiotherapy 111pembrolizumab 110Paclitaxel 96Gemcitabine 96Carboplatin 96Nivolumab 76Magnetic Resonance Spectroscopy 76Bevacizumab 76Fluorouracil 74Dexamethasone 73Radiosurgery 66Docetaxel 59Rituximab 58Leucovorin 57Oxaliplatin 55Capecitabine 55Doxorubicin 52fludarabine 51Biopsy 48durvalumab 44Cytarabine 44Drug Therapy 43Etoposide 42fludarabine phosphate 40Pemetrexed 40Radiation 39atezolizumab 36Lenalidomide 35

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Interventional × Palonosetron × Clear all
NCT01843868 2024-08-07

Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP

Australasian Leukaemia and Lymphoma Group

Phase NA Withdrawn
Lymphoid

Lymphoma, Lymphoma, Non-Hodgkin, Nausea, Vomiting

NCT03960151 2019-05-22

Rolapitant Plus Olanzapine in Multiday Cisplatin Chemotherapy

Hoosier Cancer Research Network

Phase 2 Withdrawn

Neoplasms, Germ Cell and Embryonal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡